OSRHW — OSR Holdings, Inc.

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1840425 ·
Last close
Market Cap
52W High
52W Low
ADV30
Next earnings
OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Germany, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis. In addition, the company distributes neurovascular intervention medical device and systems. OSR Holdings, Inc. is based in Bellevue, Washington.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 484,057 160,281 -3,667,184 -2,931,461 172,187,773 1,566,701 44,796,654
Dec 2025 381,269 129,704 -6,385,534 -4,822,904 171,238,248 1,700,273 44,200,845
Sep 2025 627,747 261,734 -3,803,465 -2,126,595 177,289,528 2,177,309 43,131,683
Jun 2025 1,135,517 32,782 -5,229,178 331,414 185,415,021 1,584,406 46,261,975

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-4,328,034
Investing CF
$-2,642,991
Financing CF
$8,368,171
CapEx
$-173,704
Dividends Paid
Buybacks
EPS Diluted TTM
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-37,169,881
Inventory
$196,432
Receivables
$599,065
ST Investments
$0
EBIT TTM
$-28,382,164
Pretax Income TTM
$-28,888,361
Interest Exp TTM
$506,197
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,628,591
EBITDA
$-9,626,690
Free Cash Flow
$1,384,334
Enterprise Value
Total Cash
$1,566,701
Total Debt
$4,952,793
Shares Out
Trailing EPS
Book Value
$2.92
ROE
-14.7%
ROA
-6.9%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 2,905,805 -18,336,003 -18,010,899 171,238,248 44,200,845 -4,328,034
Dec 2024 3,530,303 -11,692,197 -10,328,910 175,239,579 32,031,363 -1,849,474
Dec 2023 0 -1,830,700 403,780 36,627,733 4,108,272 -818,766
Dec 2022 0 -621,316 1,064,967 120,757,699 21,659,379 -516,309

Peers — same industry

TickerNameMarket CapLastDaily %
ISRG INTUITIVE SURGICAL INC $154.64B $436.64
SYK STRYKER CORP $119.99B $313.00
MDT Medtronic plc $99.63B $77.60
BSX BOSTON SCIENTIFIC CORP $85.67B $57.64
MMM 3M CO $80.34B $154.03

News headlines (Yahoo Finance, 1h cache)

Emerging Growth Research Issues Flash Report on OSR Holdings, Reaffirms Buy-Emerging Rating and $10.00 Price Target
2026-05-05 17:05 · Yahoo
OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026
2026-04-30 13:15 · Yahoo
OSR Holdings Executes Definitive $815 Million Global License Agreement for VXM01 with BCM Europe
2026-04-29 13:50 · Yahoo
OSR Holdings Eliminates $2.02 Million Warrant Overhang with Premium-Priced Convertible Note
2026-04-09 13:15 · Yahoo
Presenting on Emerging Growth Conference 91 Day 1 on April 1; Register to live stream
2026-03-31 11:00 · Yahoo
OSR Holdings to Update Investors at the Emerging Growth Conference on April 1, 2026
2026-03-30 13:00 · Yahoo
Emerging Growth Research Issues Flash Report on OSR Holdings, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target
2026-03-27 13:00 · Yahoo
OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level
2026-03-23 12:30 · Yahoo
Woori IO, an OSR Company, Signs NDA with Sinopharm for China Market and Global Multicenter Trials
2026-03-19 13:44 · Yahoo
Woori IO, an OSR Company, Signs NDA with Sinopharm to Explore China Commercial Opportunities
2026-03-19 12:55 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.